Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study

Archive ouverte

Rogé, Maximilien | Bowden, Patrick | Conway, Paul | Franzese, Ciro | Scorsetti, Marta | Seront, Emmanuel | Blanchard, Pierre | Terlizzi, Mario | Khalifa, Jonathan | Pasquier, Corentin | Shick, Ulrike | Siva, Shankar | Paul, Julie | Supiot, Stéphane

Edité par CCSD ; Elsevier -

International audience. Background: Management of prostate cancer (PCa) patients with lung oligometastases remains unclear in the absence of published data.Objective: The aim of this study was to evaluate the efficacy of Stereotactic Body Radiotherapy (SBRT) in this setting.Design setting and participants: We conducted a multicenter retrospective study that included 35 PCa patients treated with SBRT for lung oligometastases in 7 centers across 3 countries.Outcome measurements and statistical analysis: The efficacy was evaluated by the progression free-survival (PFS), defined as pre-SBRT PSA + 25 % or nadir PSA + 25 % and + 2 ng/mL or radiological progression if it occurred before biochemical progression. The local recurrence free-survival (LRFS), distant metastases free-survival (DMFS), Overall Survival (OS) and Androgen Deprivation Therapy free-survival were also assessed. Survival was estimated using the Kaplan Meier method.Results: 35 patients were included with lung oligometastases staged with PET-CT for 97 % and histologically biopsy confirmed for 51 %. 77 % had an oligorecurrent metastatic disease. The median pre SBRT PSA was at 1.7 ng/mL [0.8, 3.0] and the median follow-up after SBRT was 28.7 months. The median PFS was 21.6 months [95 %CI: 21.6; NA] and the median DMFS was 32.4 months [95 %CI: 22.2-NA]. No parameters were significantly associated with PFS on the univariate and multivariate models.For patients who did not start ADT before or concomitantly with SBRT (n = 18), the 1-year ADT free-survival rate was estimated at 87.2 % [71.9;100].Conclusions: SBRT for PCa lung oligometastases offers good oncological outcomes, comparable to those reported for bone and/or lymph node metastases SBRT. Our results encourage the inclusion of patients with lung oligometastatic disease in clinical trials designed to assess the value of SBRT.Patient summary: SBRT for prostate cancer lung oligometastases shows promising results, similar to treatments for bone or lymph node oligometastases.

Suggestions

Du même auteur

Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder

Archive ouverte | Khalifa, Jonathan | CCSD

International audience. Purpose: Curative radio-chemotherapy is recognized as a standard treatment option for muscle-invasive bladder cancer (MIBC). Nevertheless, the technical aspects for MIBC radiotherapy are hete...

Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology

Archive ouverte | Marvaso, Giulia | CCSD

International audience

Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus

Archive ouverte | Jereczek-Fossa, Barbara | CCSD

International audience

Chargement des enrichissements...